Ocera Forwards Liver Disease Drug After Reverse Merger With Tranzyme
This article was originally published in The Pink Sheet Daily
Executive Summary
Ocera went public by completing a reverse merger with the failing biotech Tranzyme, then completed a $20 million PIPE financing that positions it to begin a Phase IIb trial studying its lead drug for a rare liver disease.
You may also be interested in...
Gilead Buys Triangle; Viread/Coviracil Fixed-Dose Combo Launch Set For 2005
Gilead Sciences expects to launch a Viread/Coviracil fixed-dose combination treatment for HIV by 2005 following its acquisition of Coviracil developer Triangle Pharmaceuticals
With Winrevair Approved, Merck Has A Chance To Execute On CV Strategy
The activin signaling inhibitor sotatercept was approved by the US FDA for pulmonary arterial hypertension.
CinFina Pushes Early Work In Obesity In Hopes Of A Deal
Emerging Company Profile: CinFina is advancing two novel mechanisms of action in obesity as monotherapies and in combination with GLP-1s.